Featured/ SLN/ 06/24/2026 · 10:39 AM Cantor Fitzgerald Initiates Overweight Coverage on Silence Therapeutics, Calls Stock “Materially Undervalued” The firm initiated Overweight coverage citing strong divesiran Phase 2 potential and 160%+ upside.
